Cargando…

How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?

PURPOSE: This study aimed to evaluate the impact of surgical time on postoperative complications and survival outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: We retrospectively reviewed breast cancer patients treated at Breast Disease Center of the Affi...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Tianyi, Mao, Yan, Wang, Haibo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868277/
https://www.ncbi.nlm.nih.gov/pubmed/33568945
http://dx.doi.org/10.2147/CMAR.S287089
_version_ 1783648421008113664
author Ma, Tianyi
Mao, Yan
Wang, Haibo
author_facet Ma, Tianyi
Mao, Yan
Wang, Haibo
author_sort Ma, Tianyi
collection PubMed
description PURPOSE: This study aimed to evaluate the impact of surgical time on postoperative complications and survival outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: We retrospectively reviewed breast cancer patients treated at Breast Disease Center of the Affiliated Hospital of Qingdao University, from January 2013 to December 2018. The eligibility criteria were female patients with histologically confirmed primary stage II–III breast cancer and initially treated with NAC, who were <75 years old, and patients for whom medical records were available. The patients with severe comorbidities of other organs, with previous histories of other malignancies or breast cancer, and with distant metastasis or contralateral breast cancer, were excluded. Eligible patients were divided into three groups based on time to surgery (TTS): (A) ≤21 days; (B) between 21 and 28 days; and (C) >28 days. We collected medical records and followed up patients. RESULTS: Totally 422 patients were enrolled. The median TTS was 26 days. Among these patients, 119 (28.2%) were in Group A, 152 (36.0%) were in Group B, and 151 (35.8%) were in Group C. Eighty-two (19.4%) patients achieved pathologic complete response (pCR). Survival analysis showed that DFS (P=0.012) and OS (P=0.015) were significantly different among three groups. In multivariate analysis, DFS (HR=2.333, P=0.001) and OS (HR=2.783, P=0.030) were significantly worse when TTS >28 days. Postoperative complications occurred in 96 (22.7%) patients. The incidence of total postoperative complications in the three groups was statistically different (P=0.001) and Group A had worse performance. Multivariate analysis showed that age >50 years old (P=0.004) and TTS ≤21 days (P<0.001) were independent parameters for total postoperative complications. CONCLUSION: Postoperative complications and survival outcomes in breast cancer patients seemed to be influenced by TTS after the NAC. The benefits were remarkable in patients undergoing surgery between 21 and 28 days.
format Online
Article
Text
id pubmed-7868277
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78682772021-02-09 How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy? Ma, Tianyi Mao, Yan Wang, Haibo Cancer Manag Res Original Research PURPOSE: This study aimed to evaluate the impact of surgical time on postoperative complications and survival outcomes in breast cancer patients after neoadjuvant chemotherapy (NAC). PATIENTS AND METHODS: We retrospectively reviewed breast cancer patients treated at Breast Disease Center of the Affiliated Hospital of Qingdao University, from January 2013 to December 2018. The eligibility criteria were female patients with histologically confirmed primary stage II–III breast cancer and initially treated with NAC, who were <75 years old, and patients for whom medical records were available. The patients with severe comorbidities of other organs, with previous histories of other malignancies or breast cancer, and with distant metastasis or contralateral breast cancer, were excluded. Eligible patients were divided into three groups based on time to surgery (TTS): (A) ≤21 days; (B) between 21 and 28 days; and (C) >28 days. We collected medical records and followed up patients. RESULTS: Totally 422 patients were enrolled. The median TTS was 26 days. Among these patients, 119 (28.2%) were in Group A, 152 (36.0%) were in Group B, and 151 (35.8%) were in Group C. Eighty-two (19.4%) patients achieved pathologic complete response (pCR). Survival analysis showed that DFS (P=0.012) and OS (P=0.015) were significantly different among three groups. In multivariate analysis, DFS (HR=2.333, P=0.001) and OS (HR=2.783, P=0.030) were significantly worse when TTS >28 days. Postoperative complications occurred in 96 (22.7%) patients. The incidence of total postoperative complications in the three groups was statistically different (P=0.001) and Group A had worse performance. Multivariate analysis showed that age >50 years old (P=0.004) and TTS ≤21 days (P<0.001) were independent parameters for total postoperative complications. CONCLUSION: Postoperative complications and survival outcomes in breast cancer patients seemed to be influenced by TTS after the NAC. The benefits were remarkable in patients undergoing surgery between 21 and 28 days. Dove 2021-02-03 /pmc/articles/PMC7868277/ /pubmed/33568945 http://dx.doi.org/10.2147/CMAR.S287089 Text en © 2021 Ma et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Ma, Tianyi
Mao, Yan
Wang, Haibo
How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
title How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
title_full How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
title_fullStr How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
title_full_unstemmed How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
title_short How Long is It Safe to Wait for Breast Surgery After Completion of Neoadjuvant Chemotherapy?
title_sort how long is it safe to wait for breast surgery after completion of neoadjuvant chemotherapy?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868277/
https://www.ncbi.nlm.nih.gov/pubmed/33568945
http://dx.doi.org/10.2147/CMAR.S287089
work_keys_str_mv AT matianyi howlongisitsafetowaitforbreastsurgeryaftercompletionofneoadjuvantchemotherapy
AT maoyan howlongisitsafetowaitforbreastsurgeryaftercompletionofneoadjuvantchemotherapy
AT wanghaibo howlongisitsafetowaitforbreastsurgeryaftercompletionofneoadjuvantchemotherapy